Novoron Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Employees
  • 17

Employees

  • Latest Deal Type
  • Series A
  • (Upcoming)

  • Latest Deal Amount
  • $30M

  • Investors
  • 9

Novoron General Information

Description

Operator of a biotechnology company intended to develop lipoprotein-receptor drugs to repair damage and degeneration of the brain, spinal cord, and beyond. The company's current pipeline consists of pre-clinical therapies to address Alzheimer's disease, multiple sclerosis, and spinal cord injury, enabling patients suffering from conditions to recover faster from a damaged central nervous system (CNS).

Contact Information

Website
www.novoron.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 1155 Island Avenue
  • Suite 100
  • San Diego, CA 92101
  • United States
+1 (858) 000-0000

Novoron Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Novoron Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
22. Later Stage VC (Series A) $30M Upcoming Pre-Clinical Trials
20. Seed Round 19-Dec-2022 000.00 000.00 0000 Completed Pre-Clinical Trials
19. Grant 22-Apr-2022 00000 00.000 Completed Pre-Clinical Trials
17. Grant 07-Sep-2021 00000 00.000 Completed Pre-Clinical Trials
16. Grant 01-Sep-2021 00000 00.000 Completed Pre-Clinical Trials
15. Grant 01-Sep-2021 000.00 00.000 Completed Pre-Clinical Trials
14. Seed Round 07-Jul-2021 00.000 00.000 000.00 Completed Pre-Clinical Trials
13. Grant 01-Sep-2019 00000 0000 Completed Pre-Clinical Trials
12. Grant 01-Apr-2019 $1.05M $25K Completed Pre-Clinical Trials
11. Grant 01-Apr-2018 $695K $25K Completed Pre-Clinical Trials
To view Novoron’s complete valuation and funding history, request access »

Novoron Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Seed-1 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Seed 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
To view Novoron’s complete cap table history, request access »

Novoron Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biotechnology company intended to develop lipoprotein-receptor drugs to repair damage and degeneration of
Drug Discovery
San Diego, CA
17 As of 2024
000.00
000000 0

000000

um dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proide
0000000000000
Boston, MA
0 As of 0000
0000000000

000000

tation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure
0000 000000000
New Haven, CT
0 As of 0000
0000
0000000000 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Novoron Competitors (6)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
BioAxone Accelerator/Incubator Backed Boston, MA 0 0000000000
ReNetX Bio Venture Capital-Backed New Haven, CT 0 0000 0000000000 0000
Axonis Venture Capital-Backed Boston, MA 00 00.00 0000000000 00.00
NervGen Pharma Formerly Angel backed Vancouver, Canada 00 000.00 00000000 000.00
Contineum Therapeutics Formerly VC-backed San Diego, CA 00 00000 00000000 00000
To view Novoron’s complete competitors history, request access »

Novoron Executive Team (9)

Name Title Board Seat Contact Info
Travis Stiles Ph.D Co-Founder, Chief Executive Officer, CSO, President, and Chairman
Shawn Gahr Co-Founder, Chief Financial Officer, Chief Operating Officer and Board Member
Taylor Bright Ph.D Chief Operating Officer & Co-Founder
Alban Gaultier Scientific Advisory Board
Miguel de los Rios Ph.D Advisory Board Member
You’re viewing 5 of 9 executive team members. Get the full list »

Novoron Board Members (5)

Name Representing Role Since
Michael Goguen Two Bear Capital Board Member 000 0000
Shawn Gahr Novoron Co-Founder, Chief Financial Officer, Chief Operating Officer and Board Member 000 0000
Travis Stiles Ph.D Novoron Co-Founder, Chief Executive Officer, CSO, President, and Chairman 000 0000
You’re viewing 3 of 5 board members. Get the full list »

Novoron Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Novoron Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
National Institute On Aging Government Minority 000 0000 000000 0
Two Bear Capital Venture Capital Minority 000 0000 000000 0
U.S. Department of Health and Human Services Government 000 0000 000000 0
Backstage Capital Venture Capital Minority 000 0000 000000 0
RESI Conference Series Other 000 0000 000000 0
You’re viewing 5 of 9 investors. Get the full list »

Novoron FAQs

  • When was Novoron founded?

    Novoron was founded in 2014.

  • Who is the founder of Novoron?

    Travis Stiles Ph.D, Shawn Gahr, and Taylor Bright Ph.D are the founders of Novoron.

  • Who is the CEO of Novoron?

    Travis Stiles Ph.D is the CEO of Novoron.

  • Where is Novoron headquartered?

    Novoron is headquartered in San Diego, CA.

  • What is the size of Novoron?

    Novoron has 17 total employees.

  • What industry is Novoron in?

    Novoron’s primary industry is Drug Discovery.

  • Is Novoron a private or public company?

    Novoron is a Private company.

  • What is Novoron’s current revenue?

    The current revenue for Novoron is 00000.

  • How much funding has Novoron raised over time?

    Novoron has raised $15.2M.

  • Who are Novoron’s investors?

    National Institute On Aging, Two Bear Capital, U.S. Department of Health and Human Services, Backstage Capital, and RESI Conference Series are 5 of 9 investors who have invested in Novoron.

  • Who are Novoron’s competitors?

    BioAxone, ReNetX Bio, Axonis, NervGen Pharma, and Contineum Therapeutics are some of the 6 competitors of Novoron.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »